comparemela.com

Latest Breaking News On - Erik manting - Page 13 : comparemela.com

Mendus AB: Mendus to participate in upcoming conferences in December 2022 and January 2023

05.12.2022 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: 64th Annual Society of .

United statesSan franciscoMario brkuljErik mantingCorey davisLifesci advisorsValency communicationsBusiness developmentAnnual societyHealthcare meetingFight cancer daySci advisorsMendus ab

Mendus AB: Notice of extraordinary general meeting in

The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the extraordinary general meeting (“EGM”) on Friday, 18.

Mario brkuljErik mantingCorey davisLifesci advisorsEuropean parliamentValency communicationsNegma group ltdEuroclear swedenGeneral meetingGeneral data protection regulationSwedish actMats dahlbergAdvokatfirman delphiSwedish corporate governance codeCompanies actSci advisors

Mendus AB: Mendus secures manufacturing partner for establishing potential pivotal trial-stage and commercial production of DCP-001

TECH TRANSFER ALIGNS WITH CLINICAL DEVELOPMENT STRATEGY FOR DCP-001 Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced an agreement to. | October 18, 2022

Mario brkuljErik mantingLeopold berteaCorey davisLifesci advisorsEuropean society of gynecological oncologyValency communicationsMinaris regenerative medicine gmbhAcute myeloid leukemiaChief technology officerEuropean societyGynecological oncologySci advisorsMendus ab publ stock exchangePress releaseGreement immu se0005003654

Mendus AB: Mendus to report positive clinical and

RESULTS UNDERPIN DCP-001’S POTENTIAL AS A NOVEL MAINTENANCE AND INTERVENTIONAL THERAPY IN A MAJOR SOLID TUMOR INDICATION Mendus AB (“Mendus” publ;.

Mario brkuljErik mantingCorey davisDepartment of obstetricsLifesci advisorsGynaecology of the university medical centre groningenValency communicationsEuropean society of gynaecological oncologyEuropean societyGynaecological oncologyUniversity medical centre groningenChief executive officerSci advisorsNasdaq stockholmStockholm stock exchange immuMendus ab

Mendus AB: Mendus to participate in upcoming conferences in

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation.

Mario brkuljErik mantingCorey davisDepartment of obstetricsLifesci advisorsValency communicationsResearch satwinder kaur singhEdison groupEuropean society of gynaecologicaloncologyGynaecology of the university medical centre groningenBusiness developmentUniversity medical centre groningenSci advisorsNasdaq stockholmStockholm stock exchange immuMendus ab

vimarsana © 2020. All Rights Reserved.